A preprint of the study by researchers of Oxford University noted that a third dose of the AstraZeneca vaccine will also lead to a substantial increase in immune response.
UK’s drug regulator is investigating rare cases of blood clots in adults who were given Oxford-AstraZeneca shot. No safety issues have arisen in children’s trial, Oxford says.
Amid reports that doses were causing blood clot-related complications, Johnson said that six months since its discovery, multiple countries like India are producing the vaccine.
According to Oxford University researchers, the first dose of the vaccine offers 76% protection, making it safe for the interval between doses to be extended to 3 months.
India’s vaccination strategy is smartly-designed and will strengthen healthcare workers to handle a second wave, says Dr V. Ravi, former basic sciences dean at NIMHANS.
Bharat Biotech MD Dr Krishna Ella says they gave ‘excellent safety data tested on around 25,000 participants’ & their efficacy data will be available by February-March.
This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.
We now live in a world order that will keep shifting. India must use this window. This also means we remain disciplined enough not to be knee-jerked into reacting to what Pakistan sees as its moment in the sun.
COMMENTS